Micromet News
Most Popular Micromet Story
Micromet's blinatumomab shows promise in Phase I
It may be an early-stage study, but Micromet's antibody drug blinatumomab is showing promise for non-Hodgkin's lymphoma patients. In a Phase I study, all seven participants responded to the drug,... Read more...
Latest Headlines
- November 6, 2009
- October 29, 2009
- October 5, 2009
- October 3, 2008
- August 15, 2008
- March 15, 2007
- January 9, 2006
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
